Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
NC

NASDAQ · NCEL

Kadimastem Ltd

Healthcare · Biotechnology

$3.05

Down-$0.07 (-2.09%)

Updated Oct 10, 2026, 12:56 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.5M
P/E ratio
-1.69
Dividend yield
0.00%
52-week range
$1.83 – $5.12
Volume
1.59K
Avg. volume
200.47K

Price performance · NCEL

NCEL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

NCEL closed at $3.05 after 21 trading sessions, down 7.85% for the selected period.

Last close
$3.05
Period change
-7.85%
Period low
$2.85
Period high
$3.39
Daily close
View OHLC price history
NCEL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$3.02$3.0819$3.02$3.0451.59K
Oct 8, 2026$2.925$3.1101$2.89$3.117.3K
Oct 7, 2026$3.04$3.04$2.975$3.0351.47K
Oct 6, 2026$2.99$3.20$2.9159$2.96077.21K
Oct 5, 2026$2.824$2.86$2.82$2.864.09K
Oct 2, 2026$2.83$2.8712$2.7913$2.852.97K
Oct 1, 2026$2.82$2.95$2.76$2.915.18K
Sep 30, 2026$3.22$3.25$3.00$3.0752.73K
Sep 29, 2026$2.85$2.97$2.79$2.973.1K
Sep 28, 2026$2.87$3.02$2.76$2.927.2K
Sep 25, 2026$2.99$3.21$2.9465$2.94654.97K
Sep 24, 2026$2.89$2.90$2.76$2.894.16K
Sep 23, 2026$2.91$3.09$2.758$2.869.28K
Sep 22, 2026$2.96$3.37$2.90$3.03574.72K
Sep 21, 2026$3.23$3.2428$2.9001$2.9712.29K
Sep 18, 2026$3.1583$3.38$3.13$3.152.5K
Sep 17, 2026$3.295$3.39$3.15$3.3812.19K
Sep 16, 2026$3.2927$3.40$3.14$3.394.64K
Sep 15, 2026$3.35$3.35$3.31$3.322.78K
Sep 14, 2026$3.28$3.31$3.225$3.286.84K
Sep 11, 2026$3.30$3.3237$3.2239$3.30453.75K

Latest NCEL news

The latest Smart Investors Daily articles mentioning NCEL.

Stock researchCompany · Overview

NCEL research

Overview

Company profile and research snapshot.

Company profile

NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NCEL recent ratings
DateFirmRatingTarget
Jul 13, 2026Laidlaw & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 28, 2026

NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

Following successful FDA Pre-IND meeting, NewcelX advances IND-enabling activities for NCEL-101ZURICH, Sept. 28, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a regenerative medicine company developing stem-cell-derived therapies for Type 1 Diabetes (T1D), today announced that members of its senior management team will attend the Breakthrough T1D Clinical & Research Congress, taking place October 9–11, 2026, in Philadelphia, Pennsylvania. During the congress, NewcelX management will be a

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By